Command Palette

Search for a command to run...

NEPHROCARE
138.95(-3.04%)
1W: +0.32%

Nephro Care India Peer Comparison

Snapshot Summary

Nephro Care India Ltd. is currently underperforming compared to its peers in terms of financial metrics, with no reported growth or profitability metrics. Among its peers, companies like Max Healthcare and Apollo Hospitals show strong profitability and growth, while firms like Fortis Healthcare appear overvalued. Aster DM Healthcare emerges as a deep value pick despite its financial weaknesses, making it a potential target for investors focused on valuation.

  • Nephro Care India Ltd. has no reported financial metrics, indicating a lack of performance data.
  • Max Healthcare and Apollo Hospitals lead in profitability and growth metrics.
  • Aster DM Healthcare is undervalued but has low profitability metrics.
  • Fortis Healthcare is significantly overvalued with a high PE ratio.
  • Max Healthcare Institute Ltd.: Highest revenue growth (YoY: 18.49%), strong profitability (ROE: 13.47%) and reasonable debt levels.
  • Apollo Hospitals Enterprise Ltd.: High ROE (20.51%), strong EPS growth, and solid EBITDA margins.
  • Global Health Ltd.: Good revenue growth (21.56% YoY) and strong ROE (15.31%).
Stocks
CMP
Market Cap
P/E
ROCE (%)
Debt/Equity
NEPHROCARE--0.00--
MAXHEALTH₹1,179.65₹1,14,679.30Cr163.5816.26%0.14
APOLLOHOSP₹7,676.95₹1,10,383.03Cr85.1521.19%0.67
FORTIS₹924.85₹69,822.29Cr1094.6312.01%0.11
MEDANTA₹1,395.25₹37,474.60Cr81.2620.50%0.10
NH₹1,784.05₹36,459.02Cr84.5621.62%0.61
ASTERDM₹605.10₹30,225.53Cr5.0511.46%0.19

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.